Abstract
Background: The family of polypeptide Nacetylgalactosanimyltransferases (GalNAc-Ts) are important factors in glycosylation in carcinomas. The purpose of this study was to investigate the clinical significance of GalNAc-T6 and its correlation with the prognosis of epithelial ovarian carcinoma. Materials and Methods: A total of 150 patients with epithelial ovarian carcinoma were enrolled and the relationship between GalNAc-T6 expression by immunohistochemistry and long-term survival was evaluated. Results: The expression of GalNAc-T6 was positive in 57.6% (34/59) of those with serous carcinoma, 85.3% (29/34) in mucinous carcinoma, 15.6% (5/27) in clear cell carcinoma, and 44% (14/25) in endometrioid carcinoma. In a Kaplan-Meier analysis of patients with grade 1 or 2 serous carcinoma, the 10-year overall survival rates were 47.4% in the GalNAc-T6-positive and 9.1% in the GalNAc-T6-negative groups (p=0.047). Conclusion: GalNAc-T6 expression in epithelial ovarian carcinoma was different according to pathological type. In low-grade serous carcinoma, GalNAc-T6 expression may contribute to improved long-term survival.
Author supplied keywords
Cite
CITATION STYLE
Murakami, M., Kagami, S., Nguyen, T. T., Koi, C., Kurita, T., & Hachisuga, T. (2017). Expression of polypeptide n-acetylgalactosaminyltransferase-6 in epithelial ovarian carcinoma. Anticancer Research, 37(7), 3911–3915. https://doi.org/10.21873/anticanres.11773
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.